Spertino J, Curto Barredo L, Rozas Muñoz E, Figueras Nart I, Gimenez Arnau A, Serra Baldrich E, Bonfill-Ortí M, Expósito-Serrano V, Guilabert A, Melé Ninot G, Villar Buil M, Garcias Ladaria J, García Navarro X, Vilavella M, Bielsa Marsol I, Aparicio Ortiz G, Baliu Piqué C, Álvarez Abella A, Lamas Domenech N, Mascaró J M, Gómez S, Torné Gutiérrez J I, Vicente Villa A, Gimenez Arnau A
Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
Parc de Salut Mar-Hospital del Mar, Barcelona, España.
Actas Dermosifiliogr (Engl Ed). 2018 Nov;109(9):771-776. doi: 10.1016/j.ad.2018.07.005. Epub 2018 Aug 11.
Pivotal trials with omalizumab for treatment of chronic spontaneous urticaria (CSU) are generally run over 12 to 24weeks. However, in clinical practice, many patients need longer treatment. In this article, we present an algorithm for treatment with omalizumab.
The consensus document we present is the result of a series of meetings by the CSU working group of "Xarxa d'Urticària Catalana i Balear" (XUrCB) at which data from the recent literature were presented, discussed, compared, and agreed upon.
Treatment with omalizumab should be initiated at the authorized dose, and is adjusted at 3-monthly intervals according to the Urticaria Activity Score Over 7days, the Urticaria Control Test, or both.
The algorithm proposed is designed to provide guidance on how to adjust omalizumab doses, how and when to discontinue the drug, and how to reintroduce it in cases of relapse.
奥马珠单抗治疗慢性自发性荨麻疹（CSU）的关键试验通常持续12至24周。然而，在临床实践中，许多患者需要更长时间的治疗。在本文中，我们提出一种奥马珠单抗治疗方案。
我们给出的这份共识文件是“加泰罗尼亚及巴利阿里群岛荨麻疹网络”（XUrCB）的CSU工作组一系列会议的成果，会上展示、讨论、比较并认可了近期文献中的数据。
奥马珠单抗治疗应从授权剂量开始，并根据7天荨麻疹活动评分、荨麻疹控制试验或两者，每3个月调整一次剂量。
所提出的方案旨在为如何调整奥马珠单抗剂量、如何以及何时停药，以及复发时如何重新用药提供指导。
